The quality assurance concept for GMP production of non-viral bulk drug substance for use in gene therapy is briefly summarised in the following paper. The term 'non-viral gene therapy product' is generally used for therapeutical plasmid DNA. Plasmid DNA is regarded as a 'biologic'. Without addition
Quality assurance of biologics and conclusions to be drawn for gene therapy products
β Scribed by Gerd Zimmermann; Tobias Vocke; Anthony Meager
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 198 KB
- Volume
- 2
- Category
- Article
- ISSN
- 1087-8378
No coin nor oath required. For personal study only.
β¦ Synopsis
Starting with a historical outlook on the initial appearance of biological medicines in the late 19th century, the authors describe the specific features of this class of drugs and the current approaches towards their quality assurance. A brief review on currently valid strategies is given covering the specific requirements for source materials, manufacturing processes and batch release testing. Further specific features relating to licensing, standardization and control are also discussed. The authors conclude that most of the principles which have proven to be useful in the current scope of biological medicines should also be applied to gene therapy products. In addition, however, this emerging new class of products has new and unique features which create corresponding new needs in standardization and control.
π SIMILAR VOLUMES
## Section IV. What are some of the best organisms for developmental genetics? How can the study of genetic interactions help us to understand the function of complex macromolecular assemblies? How can a single mutation be used as a probe to identify other genes that are involved in the producti